ADAM17 is activated by increased binding of angiotensin II to the angiotensin II type 1 receptor(43), and the serum concentration of soluble ADAM17 was shown to be higher in severely ill COVID-19 patients(44). This evidence concerns the gene ADAM17 and COVID-19.